Cipher plans to license-in new drug this year
January 5, 2010 by leonardzehr · 1 Comment
For much of its six years as a separate company, Cipher Pharmaceuticals (TSX:DND) has been known for driving its three drugs toward the finish line. That could change in 2010. “We ramped up our in-house resources last year to look at adding pipeline opportunities, and we’ve looked at over 100 to this stage,” CEO Larry Andrews [...]
Listen to BioTuesdays 
